Novo Nordisk A/S (TSX:NOVO)

Market Cap	284.75B -24.7%
Revenue (ttm)	70.59B +8.1%
Net Income	26.26B +16.6%
EPS	5.90 +16.8%
Shares Out	n/a
PE Ratio	10.84
Forward PE	14.75
Dividend	0.52 (2.72%)
Ex-Dividend Date	Mar 30, 2026

Volume	600
Average Volume	1,843
Open	19.00
Previous Close	19.61
Day's Range	18.99 - 19.30
52-Week Range	14.94 - 26.74
Beta	n/a
RSI	65.83
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 67,900
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: NOVO

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK